SCHEMBL7148790

SCHEMBL7148790

COc1cccc(NS(=O)(=O)CCCSc2nc3ccc(OC)cc3s2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
ALDH1A1 P00352 1/20 0.50
GAA P10253 1/20 0.50
HTT P42858 1/20 0.50
POLB P06746 1/20 0.49
PDK1 Q15118 1/20 0.48
LMNA P02545 4/20 0.47
TP53 P04637 2/20 0.47
THRB P10828 2/20 0.47
MAPK1 P28482 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
CTSL P07711 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7152202 0.97 MAPT (0.49) MAPTSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL7151273 0.94 MAPT (0.52) MAPTSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL7143828 0.93 MAPT (0.46) MAPTSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL7149836 0.92 ALDH1A1 (0.51) MAPTSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL7150052 0.91 PDK1 (0.51) MAPTSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL7149832 0.91 MAPT (0.45) MAPTSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL7155045 0.89 ALDH1A1 (0.50) MAPTSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL7150971 0.88 MAPT (0.52) MAPTSMN1; SMN2POLBPDK1LMNA
SCHEMBL7146179 0.88 PDK1 (0.50) MAPTSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL7149256 0.88 MAPT (0.54) MAPTSMN1; SMN2NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642263-B2 Antitumor agents, sulfided benzothiazole derivative containing sulfonamide ICONIX PHARMACEUTICALS INC. 2003-11-04 US disclosed
US-20030176474-A1 Modulators of Rho C activity ICONIX BIOSCIENCES, INC. 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176474-A1 Modulators of Rho C activity RHOC, ARHGDIA, ROCK1 MAPT 3839/4885SMN1; SMN2 3295/4885NPC1 1040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.